Indolent Lymphoma
News
FDA approves obinutuzumab for follicular lymphoma
Approval is based on a 28% lower risk of disease progression or death after 2 years for patients on the obinutuzumab-based regimen.
From the Journals
VCR regimen showed efficacy in mantle cell and indolent lymphomas
In the 24-patient study, the 2-year progression-free survival rate was 82% and 54% respectively for MCL and iNHL patients, respectively.
News
FDA grants Priority Review to Gazyva for follicular lymphoma
Gazyva (obinutuzumab) has been granted a Priority Review by the Food and Drug Administration for the treatment of previously untreated follicular...
Conference Coverage
Copanlisib makes inroads against relapsed/refractory follicular lymphoma
LUGANO, SWITZERLAND – New PI3K inhibitor promises better safety and efficacy for ongoing treatment.
Conference Coverage
Ibrutinib/buparlisib looks good for relapsed mantle cell lymphoma
LUGANO, SWITZERLAND – The overall response rate among patients with mantle cell lymphoma in a phase I/IB dose escalation study was 100%,...
Conference Coverage
Pembrolizumab + rituximab boost response rates in relapsed follicular lymphoma
LUGANO, SWITZERLAND – The overall response rate with the combination was 65%, including 50% complete responses, in 20 patients with relapsed...
Conference Coverage
Bendamustine plus rituximab may have edge for treating indolent NHL, MCL
CHICAGO – Bendamustine plus rituximab may have some advantages for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle cell...
Conference Coverage
Lenalidomide-rituximab induces high CR rate in untreated follicular lymphoma
LUGANO, SWITZERLAND – The combination “can be a highly effective and reasonably well-tolerated treatment approach for patients with untreated...
Conference Coverage
GALEN safe and effective in relapsed and refractory follicular lymphoma
LUGANO, SWITZERLAND – Obinutuzumab, a follow-on to rituximab, appeared to be especially useful in combination with lenalidomide among patients who...
From the Journals
Subcutaneous rituximab safe, effective for follicular lymphoma
Efficacy and safety profiles were similar for subcutaneous and standard IV rituximab when given as first-line therapy to adults with follicular...
From the Journals
Ibrutinib monotherapy data in previously treated MZL is available
How might the first FDA-approved drug for MZL affect ongoing studies and treatment for the disease?